#USA #San Francisco #sepsis detection #Cytovale #IntelliSep

Cytovale's Innovative Step Forward in Sepsis Detection

Cytovale®, a pioneering medical diagnostics firm, celebrates a landmark year that has propelled its rapid sepsis detection technology, IntelliSep®, to the forefront of the healthcare industry. As the demand for timely and accurate sepsis diagnosis escalates, Cytovale's proactive approach has not only enhanced patient outcomes but also led to substantial growth and recognition in the field.

In 2024, after the first year of commercialization, Cytovale expanded its reach significantly, acquiring a diverse customer base spanning three states and two major health systems. IntelliSep®, which has received approval from the U.S. Food and Drug Administration (FDA), has proven its capability by analyzing responses from over 15,000 patients exhibiting signs of sepsis. The solution harnesses advanced AI technology, utilizing high-speed cameras and microfluidics to deliver results in roughly eight minutes, allowing for swift decision-making in emergency departments.

The importance of early detection in managing sepsis cannot be overstated. Each year, sepsis leads to exorbitant costs in the U.S. healthcare system, totaling around $62 billion. The imperative for effective detection tools has never been clearer, as conventional methods often fall short in emergency scenarios. IntelliSep® stands out as a first-of-its-kind tool that not only identifies but also rules out sepsis through comprehensive biological analyses of white blood cells, all based on a standard blood sample.

Transforming Patient Care and Hospital Efficiency

Cytovale's impact can be observed across various healthcare settings. Hospitals using IntelliSep® have reported remarkable clinical improvements. In its pilot phase at Our Lady of the Lake Regional Medical Center in Baton Rouge, Louisiana, IntelliSep® contributed to a 30% reduction in the risk-adjusted mortality index for sepsis patients and cut treatment times by an impressive 60 to 70 minutes. Moreover, it has facilitated shorter hospital stays, saving an average of $1,429 per patient.

The success of IntelliSep® has led the Franciscan Missionaries of Our Lady Health System (FMOLHS) to expand its implementation across other facilities in Louisiana and Mississippi, reinforcing its efficacy as a vital tool for patient management. Additionally, another health network, Froedtert in Wisconsin, has begun pilot screening using IntelliSep®, marking its growing acceptance in diverse healthcare environments.

Cytovale's innovative contributions to sepsis diagnostics have garnered an array of accolades in recent months. The company received recognition from the Digital Health Hub Foundation for